



## Clinical trial results:

### Single Dose, Open Label Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Three Different Eplivanserin Doses in Children Aged 6-17 Years With Insomnia of Various Origins

#### Summary

EudraCT number	2014-004644-35
Trial protocol	Outside EU/EEA
Global end of trial date	29 December 2009

#### Results information

Result version number	v1 (current)
This version publication date	13 April 2016
First version publication date	06 June 2015

#### Trial information

##### Trial identification

Sponsor protocol code	PKD10491
-----------------------	----------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00913614
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Sanofi U.S Services Inc.
Sponsor organisation address	55 Corporate Drive Bridgewater, New Jersey, United States, 08807
Public contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
Scientific contact	Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-000114-PIP01-07
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	29 January 2010
Is this the analysis of the primary completion data?	No

---

Global end of trial reached?	Yes
Global end of trial date	29 December 2009
Was the trial ended prematurely?	Yes

---

Notes:

---

**General information about the trial**

---

Main objective of the trial:

There are 2 primary objectives in this trial:

To assess the safety and tolerability after administration of single ascending oral doses of eplivanserin to children aged 6-17 years with insomnia of various origins.

To assess the pharmacokinetics of eplivanserin (and active metabolite: SR141342) after administration of single ascending oral doses of eplivanserin to children aged 6-17 years with insomnia of various origins.

---

Protection of trial subjects:

The study was conducted by investigators experienced in the treatment of pediatric subjects. The parent(s) or guardian(s) as well as the children were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time. In addition to the consent form for the parent(s)/guardian(s), an assent form in child-appropriate language was provided and explained to the child. Repeated invasive procedures were minimized. The number of blood samples as well as the amount of blood drawn were adjusted according to age and weight. A topical anesthesia may have been used to minimize distress and discomfort.

---

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	11 May 2009
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

---

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

Country: Number of subjects enrolled	United States: 41
Worldwide total number of subjects	41
EEA total number of subjects	0

---

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0

---

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	21
Adolescents (12-17 years)	20
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 10 sites in the United States of America. A total of 41 subjects were enrolled between 11 May 2009 and 10 December 2009.

### Pre-assignment

Screening details:

All 41 enrolled subjects were treated.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Eplivanserin 0.01 mg/kg: 6-11 years

Arm description:

Single dose of Eplivanserin on day 1.

Arm type	Experimental
Investigational medicinal product name	Eplivanserin
Investigational medicinal product code	SR46349
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Eplivanserin 0.01 mg/kg before the subjects' normal bedtime.

<b>Arm title</b>	Eplivanserin 0.035 mg/kg: 6-11 years
------------------	--------------------------------------

Arm description:

Single dose of Eplivanserin on day 1.

Arm type	Experimental
Investigational medicinal product name	Eplivanserin
Investigational medicinal product code	SR46349
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Eplivanserin 0.035 mg/kg before the subjects' normal bedtime.

<b>Arm title</b>	Eplivanserin 0.07 mg/kg: 6-11 years
------------------	-------------------------------------

Arm description:

Single dose of Eplivanserin on day 1.

Arm type	Experimental
Investigational medicinal product name	Eplivanserin
Investigational medicinal product code	SR46349
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Eplivanserin 0.07 mg/kg before the subjects' normal bedtime.

<b>Arm title</b>	Eplivanserin 0.01 mg/kg: 12-17 years
------------------	--------------------------------------

Arm description:

Single dose of Eplivanserin on day 1.

Arm type	Experimental
Investigational medicinal product name	Eplivanserin
Investigational medicinal product code	SR46349
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Eplivanserin 0.01 mg/kg before the subjects' normal bedtime.

<b>Arm title</b>	Eplivanserin 0.035 mg/kg: 12-17 years
------------------	---------------------------------------

Arm description:

Single dose of Eplivanserin on day 1.

Arm type	Experimental
Investigational medicinal product name	Eplivanserin
Investigational medicinal product code	SR46349
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Eplivanserin 0.035 mg/kg before the subjects' normal bedtime.

<b>Arm title</b>	Eplivanserin 0.07 mg/kg: 12-17 years
------------------	--------------------------------------

Arm description:

Single dose of Eplivanserin on day 1.

Arm type	Experimental
Investigational medicinal product name	Eplivanserin
Investigational medicinal product code	SR46349
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Eplivanserin 0.07 mg/kg before the subjects' normal bedtime.

<b>Number of subjects in period 1</b>	Eplivanserin 0.01 mg/kg: 6-11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.07 mg/kg: 6-11 years
Started	7	7	7
Treated	7	7	7
Completed	7	7	6
Not completed	0	0	1
Lost to follow-up	-	-	1

<b>Number of subjects in period 1</b>	Eplivanserin 0.01 mg/kg: 12-17 years	Eplivanserin 0.035 mg/kg: 12-17 years	Eplivanserin 0.07 mg/kg: 12-17 years
Started	7	7	6
Treated	7	7	6
Completed	7	7	6
Not completed	0	0	0
Lost to follow-up	-	-	-

## Baseline characteristics

### Reporting groups

Reporting group title	Eplivanserin 0.01 mg/kg: 6-11 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.035 mg/kg: 6-11 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.07 mg/kg: 6-11 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.01 mg/kg: 12-17 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.035 mg/kg: 12-17 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.07 mg/kg: 12-17 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	

Reporting group values	Eplivanserin 0.01 mg/kg: 6-11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.07 mg/kg: 6-11 years
Number of subjects	7	7	7
Age categorical			
Units: Subjects			
Children (2-11 years)	7	7	7
Adolescents (12-17 years)	0	0	0
Gender categorical			
Units: Subjects			
Female	3	2	3
Male	4	5	4

Reporting group values	Eplivanserin 0.01 mg/kg: 12-17 years	Eplivanserin 0.035 mg/kg: 12-17 years	Eplivanserin 0.07 mg/kg: 12-17 years
Number of subjects	7	7	6
Age categorical			
Units: Subjects			
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	7	7	6
Gender categorical			
Units: Subjects			
Female	2	3	4
Male	5	4	2

Reporting group values	Total		
Number of subjects	41		

Age categorical Units: Subjects			
Children (2-11 years)	21		
Adolescents (12-17 years)	20		
Gender categorical Units: Subjects			
Female	17		
Male	24		



## End points

### End points reporting groups

Reporting group title	Eplivanserin 0.01 mg/kg: 6-11 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.035 mg/kg: 6-11 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.07 mg/kg: 6-11 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.01 mg/kg: 12-17 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.035 mg/kg: 12-17 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	
Reporting group title	Eplivanserin 0.07 mg/kg: 12-17 years
Reporting group description:	
Single dose of Eplivanserin on day 1.	

### Primary: Pharmacokinetic (PK) Parameters: Area Under Curve (AUC 0-24) of Eplivanserin and SR141342

End point title	Pharmacokinetic (PK) Parameters: Area Under Curve (AUC 0-24) of Eplivanserin and SR141342 <sup>[1][2]</sup>
End point description:	Analysis was performed on Pharmacokinetic population which included all subjects with no major deviations related to study drug intake, for whom the primary pharmacokinetic data was considered sufficient and interpretable.
End point type	Primary
End point timeframe:	1, 3, 6, 24 hours post-dose on Day 1

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The purpose was to provide descriptive statistics only.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis of PK focused only on 0.01 and 0.035 mg/kg/day of eplivanserin in children 6 to 11 and 12 to 17 years of age.

End point values	Eplivanserin 0.01 mg/kg: 6-11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.01 mg/kg: 12-17 years	Eplivanserin 0.035 mg/kg: 12-17 years
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	7	7
Units: ng*h/mL				
arithmetic mean (standard deviation)				
Eplivanserin AUC 0-24	7.69 (± 2.14)	33.5 (± 3.95)	9.28 (± 2.24)	47.8 (± 16.1)
SR141342 AUC 0-24	1.52 (± 0.578)	7.55 (± 1.81)	1.71 (± 0.495)	7.39 (± 2.16)

## Statistical analyses

No statistical analyses for this end point

### Primary: Maximum plasma concentration (Cmax) of Eplivanserin and SR141342

End point title	Maximum plasma concentration (Cmax) of Eplivanserin and SR141342 <sup>[3]</sup> <sup>[4]</sup>
-----------------	--

End point description:

Analysis was performed on pharmacokinetic population.

End point type	Primary
----------------	---------

End point timeframe:

1, 3, 6, 24 hours post-dose on Day 1

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The purpose was to provide descriptive statistics only.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis of PK focused only on 0.01 and 0.035 mg/kg/day of eplivanserin in children 6 to 11 and 12 to 17 years of age.

End point values	Eplivanserin 0.01 mg/kg: 6- 11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.01 mg/kg: 12-17 years	Eplivanserin 0.035 mg/kg: 12-17 years
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	7	7
Units: ng/mL				
arithmetic mean (standard deviation)				
Eplivanserin: Cmax	0.582 (± 0.202)	2.25 (± 0.337)	0.666 (± 0.181)	2.98 (± 0.745)
SR141342: Cmax	0.0852 (± 0.0215)	0.422 (± 0.0832)	0.0891 (± 0.0248)	0.412 (± 0.122)

## Statistical analyses

No statistical analyses for this end point

### Primary: Overview of Treatment-Emergent Adverse Events (TEAE)

End point title	Overview of Treatment-Emergent Adverse Events (TEAE) <sup>[5]</sup>
-----------------	---

End point description:

Analysis was performed on safety population defined as all randomized and treated population regardless of the amount of treatment administered.

End point type	Primary
----------------	---------

End point timeframe:

Baseline up to end of the study (Day 17 - 20)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The purpose was to provide descriptive statistics only.

End point values	Eplivanserin 0.01 mg/kg: 6- 11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.07 mg/kg: 6- 11 years	Eplivanserin 0.01 mg/kg: 12-17 years
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	7	7	7	7
Units: subjects				
Any TEAE	3	1	3	2
Any severe TEAE	0	0	0	0
Any serious TEAE	0	0	0	0

End point values	Eplivanserin 0.035 mg/kg: 12-17 years	Eplivanserin 0.07 mg/kg: 12-17 years		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	7	6		
Units: subjects				
Any TEAE	4	3		
Any severe TEAE	0	0		
Any serious TEAE	0	0		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Global Sleep Parameters

End point title	Global Sleep Parameters
-----------------	-------------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Immediately following single dose administration

End point values	Eplivanserin 0.01 mg/kg: 6- 11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.07 mg/kg: 6- 11 years	Eplivanserin 0.01 mg/kg: 12-17 years
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[6]</sup>	0 <sup>[7]</sup>	0 <sup>[8]</sup>	0 <sup>[9]</sup>
Units: not analysed				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

- [6] - The study was prematurely discontinued, hence no statistical analysis have been performed.  
[7] - The study was prematurely discontinued, hence no statistical analysis have been performed.  
[8] - The study was prematurely discontinued, hence no statistical analysis have been performed.  
[9] - The study was prematurely discontinued, hence no statistical analysis have been performed.

End point values	Eplivanserin 0.035 mg/kg: 12-17 years	Eplivanserin 0.07 mg/kg: 12-17 years		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[10]</sup>	0 <sup>[11]</sup>		
Units: not analysed				
arithmetic mean (standard deviation)	()	()		

Notes:

- [10] - The study was prematurely discontinued, hence no statistical analysis have been performed.  
[11] - The study was prematurely discontinued, hence no statistical analysis have been performed.

## Statistical analyses

No statistical analyses for this end point

## Secondary: Sleep Architecture

End point title	Sleep Architecture
End point description:	
End point type	Secondary
End point timeframe:	
Immediately following single dose administration	

End point values	Eplivanserin 0.01 mg/kg: 6- 11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.07 mg/kg: 6- 11 years	Eplivanserin 0.01 mg/kg: 12-17 years
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 <sup>[12]</sup>	0 <sup>[13]</sup>	0 <sup>[14]</sup>	0 <sup>[15]</sup>
Units: not analysed				
arithmetic mean (standard deviation)	()	()	()	()

Notes:

- [12] - The study was prematurely discontinued, hence no statistical analysis have been performed.  
[13] - The study was prematurely discontinued, hence no statistical analysis have been performed.  
[14] - The study was prematurely discontinued, hence no statistical analysis have been performed.  
[15] - The study was prematurely discontinued, hence no statistical analysis have been performed.

End point values	Eplivanserin 0.035 mg/kg: 12-17 years	Eplivanserin 0.07 mg/kg: 12-17 years		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 <sup>[16]</sup>	0 <sup>[17]</sup>		
Units: not analysed				
arithmetic mean (standard deviation)	()	()		

---

Notes:

[16] - The study was prematurely discontinued, hence no statistical analysis have been performed.

[17] - The study was prematurely discontinued, hence no statistical analysis have been performed.

---

## **Statistical analyses**

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 17-20) regardless of seriousness or relationship to investigational product.

Adverse event reporting additional description:

Reported adverse events are treatment-emergent adverse events that is AEs that developed/worsened during the 'on treatment period' (from the time of study drug administration up to the end of study visit [included]).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	12.1
--------------------	------

### Reporting groups

Reporting group title	Eplivanserin 0.01 mg/kg: 6-11 years
-----------------------	-------------------------------------

Reporting group description:

Single dose of Eplivanserin on day 1.

Reporting group title	Eplivanserin 0.035 mg/kg: 6-11 years
-----------------------	--------------------------------------

Reporting group description:

Single dose of Eplivanserin on day 1.

Reporting group title	Eplivanserin 0.07 mg/kg: 6-11 years
-----------------------	-------------------------------------

Reporting group description:

Single dose of Eplivanserin on day 1.

Reporting group title	Eplivanserin 0.01 mg/kg: 12-17 years
-----------------------	--------------------------------------

Reporting group description:

Single dose of Eplivanserin on day 1.

Reporting group title	Eplivanserin 0.035 mg/kg: 12-17 years
-----------------------	---------------------------------------

Reporting group description:

Single dose of Eplivanserin on day 1.

Reporting group title	Eplivanserin 0.07 mg/kg: 12-17 years
-----------------------	--------------------------------------

Reporting group description:

Single dose of Eplivanserin on day 1.

Serious adverse events	Eplivanserin 0.01 mg/kg: 6-11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.07 mg/kg: 6-11 years
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 7 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			

Serious adverse events	Eplivanserin 0.01 mg/kg: 12-17 years	Eplivanserin 0.035 mg/kg: 12-17 years	Eplivanserin 0.07 mg/kg: 12-17 years
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
number of deaths (all causes)	0	0	0

number of deaths resulting from adverse events			
--	--	--	--

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	Eplivanserin 0.01 mg/kg: 6-11 years	Eplivanserin 0.035 mg/kg: 6-11 years	Eplivanserin 0.07 mg/kg: 6-11 years
Total subjects affected by non-serious adverse events subjects affected / exposed	3 / 7 (42.86%)	1 / 7 (14.29%)	3 / 7 (42.86%)
Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Injury, poisoning and procedural complications Accidental overdose subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Excoriation subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Animal bite subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Skin laceration subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Head injury subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Arthropod bite subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Sunburn			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Cardiac disorders Sinus tachycardia subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0
Nervous system disorders Somnolence subjects affected / exposed occurrences (all)  Lethargy subjects affected / exposed occurrences (all)  Headache subjects affected / exposed occurrences (all)	2 / 7 (28.57%) 2  1 / 7 (14.29%) 1  0 / 7 (0.00%) 0	0 / 7 (0.00%) 0  0 / 7 (0.00%) 0  0 / 7 (0.00%) 0	1 / 7 (14.29%) 1  0 / 7 (0.00%) 0  0 / 7 (0.00%) 0
General disorders and administration site conditions Irritability subjects affected / exposed occurrences (all)  Fatigue subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1  0 / 7 (0.00%) 0	0 / 7 (0.00%) 0  0 / 7 (0.00%) 0	0 / 7 (0.00%) 0  0 / 7 (0.00%) 0
Ear and labyrinth disorders Tinnitus subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Eye disorders Lacrimation increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Gastrointestinal disorders Abdominal pain upper subjects affected / exposed occurrences (all)  Vomiting	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0



subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Nasal congestion subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Hiccups subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Skin and subcutaneous tissue disorders Photosensitivity reaction subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Musculoskeletal and connective tissue disorders Neck pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Infections and infestations Tooth abscess subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Lymphadenitis viral subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0

<b>Non-serious adverse events</b>	Eplivanserin 0.01 mg/kg: 12-17 years	Eplivanserin 0.035 mg/kg: 12-17 years	Eplivanserin 0.07 mg/kg: 12-17 years
Total subjects affected by non-serious adverse events			

subjects affected / exposed	2 / 7 (28.57%)	4 / 7 (57.14%)	3 / 6 (50.00%)
Investigations			
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Excoriation			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Fall			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Animal bite			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Skin laceration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Head injury			
subjects affected / exposed	0 / 7 (0.00%)	1 / 7 (14.29%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Arthropod bite			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Sunburn			
subjects affected / exposed	1 / 7 (14.29%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Cardiac disorders			
Sinus tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 7 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			

Somnolence subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0
Lethargy subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	2 / 7 (28.57%) 2	1 / 6 (16.67%) 1
General disorders and administration site conditions			
Irritability subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	1 / 6 (16.67%) 2
Ear and labyrinth disorders			
Tinnitus subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0
Eye disorders			
Lacrimation increased subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1
Gastrointestinal disorders			
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 6 (16.67%) 1
Vomiting subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0
Stomatitis subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			

Nasal congestion subjects affected / exposed occurrences (all)	1 / 7 (14.29%) 1	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0
Hiccups subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0
Skin and subcutaneous tissue disorders Photosensitivity reaction subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	1 / 6 (16.67%) 2
Musculoskeletal and connective tissue disorders Neck pain subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 2	0 / 6 (0.00%) 0
Infections and infestations Tooth abscess subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0
Lymphadenitis viral subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	1 / 7 (14.29%) 1	0 / 6 (0.00%) 0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
18 June 2009	It included following statements: Change in pharmacokinetic sampling to ensure optimal conditions to measure eplivanserin and SR141342 half-lives, change in exclusion criteria (reinforced exclusion of illicit drugs), additional ECG measurement (Superimposed median) that was more appropriate for pediatric subjects, change in destination of pharmacokinetic specimen collection shipments and clerical changes for greater understanding.
14 September 2009	It included following points: Subjects taking CYP2B6 inhibitors and CYP3A4 inducers as concomitant drugs should be excluded and also subjects with abnormal hepatic function (eg, alkaline phosphatase > Upper Limit of Normal range [ULN], total bilirubin > ULN [except in Gilbert's Syndrome], Alanine aminotransferase [ALT] > ULN).

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported